Navigation Links
MinuteClinic Says Rand Corporation Study in Annals of Internal Medicine Study on Quality, Affordable Care at Retail Clinics Affirms Internal Information
Date:8/31/2009

In the Rand study researchers reviewed the experiences of 2,100 patients treated in clinics in Minnesota in 2005 and 2006 for middle ear infections, sore throats or urinary tract infections. The quality of medical care was judged using 14 indicators of quality and whether patients received seven preventative care services during the initial and additional visits over three months in doctors' offices, urgent care centers and hospital emergency departments. The study is published in the September 1 edition of the Annals of Internal Medicine.

MinuteClinic health care centers are staffed by nurse practitioners who specialize in family health care and are trained to diagnose, treat and write prescriptions for common family illnesses such as strep throat and ear, eye, sinus, bladder and bronchial infections. Minor wounds, abrasions and joint sprains are treated, and common vaccinations such as influenza, tetanus, MMR, and Hepatitis A & B are available at all locations. In addition, MinuteClinic administers a series of wellness services designed to help consumers identify lifestyle changes needed to improve their current and future health, including screenings for diabetes, hypertension and obesity.

About MinuteClinic

Minneapolis-based MinuteClinic is a subsidiary of CVS Caremark Corporation (NYSE: CVS), the No. 1 provider of prescriptions and related health care services in the nation. MinuteClinic launched the first retail health care centers in the United States in 2000 and is the first provider to establish a national presence with about 500 locations in 25 states. By creating a health care delivery model that responds to consumer demand, MinuteClinic makes access to high-quality medical treatment easier for more Americans. The company has generated more than 4 million p
'/>"/>

SOURCE MinuteClinic
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Video: CVS/pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot
2. MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes
3. CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic
4. American CareSource Holdings Increases ACS Networks Convenience and Quality With MinuteClinic Signing
5. CVS/pharmacy and MinuteClinic Receive Award of Excellence from National Influenza Vaccine Summit
6. MinuteClinic Becomes Participating Provider in All CareFirst BlueCross BlueShield Plans
7. MinuteClinic is Educating Consumers About Swine Flu
8. MinuteClinic Becomes Participating Provider With Highmark Inc.
9. MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families
10. Cleveland Clinic Enters into Agreement with MinuteClinic
11. MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 62585 1Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 62585 2Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 62585 3Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 1Senate Approval of Mikulski Amendment Further Opens Health Care Bill to Massive Federal Funding of Abortion 62581 2Ginger Prices Could Skyrocket on H1N1 Fears 62576 1Ginger Prices Could Skyrocket on H1N1 Fears 62576 2